Category Archives: Genetics

By RTT News, September 10, 2014, 12:14:00 PM EDT (RTTNews.com) - Seattle Genetics Inc ( SGEN ) and Genmab A/S (GNMSF.PK) on Wednesday entered into an additional antibody-drug conjugate collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics' auristatin-based Antibody-Drug Conjugate (ADC) technology with Genmab's HuMax-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmab's initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization. Seattle Genetics and Genmab entered into an ADC collaboration for HuMax-TF-ADC in September 2010. HuMax-TF-ADC, targeting the Tissue Factor antigen, is in a Phase I trial for solid tumors. Seattle Genetics has the right to exercise a co-development option to share all future … Continue reading →

Myriad Genetics, Inc. ( MYGN ) reported encouraging results from a pivotal clinical utility study of its myPath Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago. myPath Melanoma is a clinically validated gene expression molecular test that has been designed to differentiate malignant melanoma from benign skin lesions, with more than 90% accuracy. This study evaluated 687 pigmented skin lesions submitted by 42 dermatopathologists who were then asked to document their diagnosis, level of confidence, further testing and treatment recommendations, both pre- and post-receipt of the myPath test results. The results showed that 35% of these dermatologists revised their treatment recommendation after receiving the myPath Melanoma test score. Moreover, the test score led to a 76% reduction in "indeterminate" diagnoses. According to Myriad, these data support the integration of myPath Melanoma into clinical practice for improvement of the diagnosis of melanoma, thereby enhancing the scope of patient care. With certain melanomas imitating benign skin lesions, it becomes quite difficult for clinicians to diagnose the former in patients accurately. In such situations, Myriad myPath Melanoma comes of help as it has the ability to discriminate malignant melanoma from benign skin lesions. Management at Myriad strongly … Continue reading →

Seattle Genetics, Inc. today announced that the companies have entered into an additional antibody-drug conjugate collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics auristatin-based ADC technology with Genmabs HuMax-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmabs initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization. This collaboration with Genmab further extends the reach of our industry-leading ADC technology for use with novel oncology targets, while providing us with a compelling financial value proposition as the program advances, said Natasha Hernday, Vice President, Corporate Development at Seattle Genetics. Genmabs impressive track record in the development of antibody-based therapies for the treatment of cancer, including an … Continue reading →

Laser Genetics ND3x50 Sub Zero Laser Designator - OpticsPlanet.com Product in Focus Get the Laser Genetics ND 3x50 Sub-Zero Laser Designator at OpticsPlanet.com! http://www.opticsplanet.com/laser-genetics-nd-3-x-50mm-sub-zero-laser-designator-w-scope-mount.html?utm_source=youtube ... By: OpticsPlanet … Continue reading →

Sheepdog herding and genetics - Sci Cam 014 - 9th September 2014 Online Science Magazine show - watch and ask questions. In this episode we'll be talking about how you model sheepdog herding and what plants have told us our the inheritance of genes. By: Sci Cam … Continue reading →

Y10 Science Genetics and Evolution Revision Part 3 By: Chris Heath … Continue reading →

PUBLIC RELEASE DATE: 9-Sep-2014 Contact: Ronald Rogers rrogers@myriad.com 801-584-3065 Myriad Genetics, Inc. http://www.twitter.com/myriad SALT LAKE CITY, Utah, Sept. 9, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today presented results from a pivotal clinical utility study of the Myriad myPath Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a novel diagnostic test that differentiates malignant melanoma from benign skin lesions with greater than 90 percent accuracy and helps physicians deliver a more objective and confident diagnosis for patients. This study evaluated the impact of the myPath Melanoma diagnostic test on expert dermatopathologists' diagnoses and treatment recommendations for patients. The analysis included 687 cases of pigmented skin lesions submitted by 42 leading dermatopathologists in the United States. These melanoma experts were asked to document their diagnosis, level of confidence, any further testing and recommendations for treatment both before and after receiving the myPath test results. The results show that when the myPath Melanoma test score was provided to the dermatopathologists, they revised their treatment recommendations in 35 percent of cases. Additionally, the myPath test score led to a 76 percent reduction in "indeterminate" diagnoses. These data strongly support the integration of myPath … Continue reading →

PUBLIC RELEASE DATE: 8-Sep-2014 Contact: Raeka Aiyar, Ph.D. raeka.aiyar@gmail.com 202-412-1120 Genetics Society of America http://www.twitter.com/GeneticsGSA BETHESDA, MD The Genetics Society of America (GSA) and the yeast genetics research community are pleased to announce the winners of the GSA poster awards at the 2014 Yeast Genetics Meeting, which took place in Seattle, WA, July 29August 3, 2014. These awards were made to undergraduate, graduate, and postdoctoral scientists in recognition of the research they presented at the conference. Their projects examined the molecular basis of several processes governing the inheritance of traits using yeast as a model organism. "The breadth and depth of the science presented at this meeting was impressive and inspiring," remarked Adam Fagen, PhD, GSA's executive director. "We are very proud to see these significant contributions to genetics research from these early career scientists and look forward to following their continued success throughout their careers." Nearly 400 research posters were presented at the meeting, and the winning posters were selected by a panel of leading yeast genetics researchers. The winners of the 2014 Yeast Genetics Meeting GSA Poster Awards are as follows: First Place: Joseph Sanchez (PhD student, University of Washington) Advisor: Dr. Bonny Brewer Title:: "The human Meier-Gorlin … Continue reading →

Let's Play The Sims 3: Perfect Genetics pt 21 I created this video with the YouTube Video Editor (http://www.youtube.com/editor) By: Simmerlover3 … Continue reading →

#484 GENETICS Proven Genetic of 2014 Heifer, Sired by Dr. Too, out of a Just Push Play daughter. By: SpearWbuckingbulls … Continue reading →